Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial
| Autor: | Kaku, K, Enya, K, Nakaya, R, Ohira, T, Matsuno, R |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
fasiglifam
GPR40 TAK-875 Blood Glucose Glycated Hemoglobin Male Original Articles Middle Aged Hypoglycemia Receptors G-Protein-Coupled Japanese patients Asian People Diabetes Mellitus Type 2 Double-Blind Method Japan Diet Diabetic Humans Hypoglycemic Agents Female type 2 diabetes Sulfones Exercise Aged Benzofurans |
| Zdroj: | Diabetes, Obesity & Metabolism |
| ISSN: | 1463-1326 1462-8902 |
| Popis: | Aim To assess the efficacy and safety of fasiglifam 25 and 50 mg in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise. Methods This phase III, double-blind, placebo-controlled, multicentre study included 192 patients randomized to once-daily treatment with fasiglifam 25 mg (n = 63) or 50 mg (n = 62) or placebo (n = 67) for 24 weeks. The primary efficacy endpoint was the change from baseline in glycated haemoglobin (HbA1c) at week 24. Results At week 24, both fasiglifam groups had significantly reduced HbA1c levels compared with the placebo group (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text